Metabolic
Semaglutide
GLP-1 receptor agonist · NN9535
Long-acting GLP-1 receptor agonist — the reference compound for incretin-based metabolic research.
5 mg10 mg15 mg20 mg30 mg
Tirzepatide
Also known as: GIP/GLP-1 dual agonist · LY3298176
Metabolic & GLP-1 In stock Box of 10 vials 1 reference
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| TR5 | 5 mg | 10 vials / box | |
| TR10 | 10 mg | 10 vials / box | |
| TR15 | 15 mg | 10 vials / box | |
| TR20 | 20 mg | 10 vials / box | |
| TR30 | 30 mg | 10 vials / box | |
| TR40 | 40 mg | 10 vials / box | |
| TR50 | 50 mg | 10 vials / box | |
| TR60 | 60 mg | 10 vials / box | |
| TR100 | 100 mg | 10 vials / box | |
| TR120 | 120 mg | 10 vials / box |
Order Tirzepatide
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, modified to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. A C20 fatty-diacid moiety provides albumin binding and once-weekly pharmacokinetics.
In SURMOUNT-1 (n = 2,539; 72 weeks), the mean body-weight change was −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg respectively, versus −3.1% with placebo 1. Its dual-agonist pharmacology makes it a key comparator in research on incretin receptor cross-talk.
At a glance
- Balanced GIP + GLP-1 receptor activity in one molecule
- Phase 3 evidence: SURMOUNT and SURPASS programmes
- Widest size range in our catalogue: 5 mg through 120 mg vials
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
- Formula
- C225H348N48O68
- Mol. weight
- 4813.5 g/mol
- CAS No.
- 2023788-19-2
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.
Related
Often ordered together
Metabolic
Retatrutide
GGG triple agonist · LY3437943
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
5 mg10 mg15 mg20 mg30 mg +4
Metabolic Blend
Retatrutide + Tirzepatide
Triple + dual agonist blend
High-mass co-formulation of retatrutide and tirzepatide for combination-agonist studies.
60 mg (20 + 40)